Errata for ICD-O-3 Site/Type Validation List

The ICD-O-3 Site/Type Validation program was modified to only allow for the site/histology/behavior combinations listed in this publication. All other cases must be reviewed.

The following site/histology combinations were added to the list.

<table>
<thead>
<tr>
<th>Primary Site</th>
<th>Histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>C150-C155,C158-C159</td>
<td>9680/3 ML, large B-cell, diffuse</td>
</tr>
<tr>
<td>C170-C173,C178-C179</td>
<td>8152/3 Glucagonoma, malignant</td>
</tr>
<tr>
<td>C260,C268-C269</td>
<td>8152/3 Glucagonoma, malignant</td>
</tr>
<tr>
<td>C440-C449</td>
<td>9751/3 Langerhans cell histiocytosis, NOS</td>
</tr>
<tr>
<td>C470-C476,C478-C479,C490-C496,C498-C499</td>
<td>9726/3 Primary Cutaneous gamma-delta T-cell lymphoma</td>
</tr>
<tr>
<td>C510-C518,C529</td>
<td>9597/3 Primary Cutaneous follicle centre lymphoma</td>
</tr>
<tr>
<td></td>
<td>9700/3 Mycosis fungoides</td>
</tr>
<tr>
<td></td>
<td>9708/3 Subcutaneous panniculitis-like T-cell lymphoma</td>
</tr>
<tr>
<td></td>
<td>9709/3 Cutaneous T-cell lymphoma, NOS</td>
</tr>
<tr>
<td></td>
<td>9718/3 Primary cutan. CD30+ T-cell lymphoprolif. Disorder</td>
</tr>
<tr>
<td></td>
<td>9725/3 Hydroa vacciniforme-like lymphoma</td>
</tr>
<tr>
<td></td>
<td>9726/3 Primary Cutaneous gamma-delta T-cell lymphoma</td>
</tr>
<tr>
<td>C519</td>
<td>9597/3 Primary Cutaneous follicle centre lymphoma</td>
</tr>
<tr>
<td></td>
<td>9700/3 Mycosis fungoides</td>
</tr>
<tr>
<td></td>
<td>9708/3 Subcutaneous panniculitis-like T-cell lymphoma</td>
</tr>
<tr>
<td></td>
<td>9709/3 Cutaneous T-cell lymphoma, NOS</td>
</tr>
<tr>
<td></td>
<td>9718/3 Primary cutan. CD30+ T-cell lymphoprolif. Disorder</td>
</tr>
<tr>
<td></td>
<td>9725/3 Hydroa vacciniforme-like lymphoma</td>
</tr>
<tr>
<td></td>
<td>9726/3 Primary Cutaneous gamma-delta T-cell lymphoma</td>
</tr>
<tr>
<td>C530-C531,C538-C539</td>
<td>8098/3 Adenoid basal cell carcinoma</td>
</tr>
<tr>
<td>C600-C608,C608-C609,C632</td>
<td>9597/3 Primary Cutaneous follicle centre lymphoma</td>
</tr>
<tr>
<td></td>
<td>9700/3 Mycosis fungoides</td>
</tr>
<tr>
<td></td>
<td>9701/3 Sezary syndrome</td>
</tr>
<tr>
<td></td>
<td>9708/3 Subcutaneous panniculitis-like T-cell lymphoma</td>
</tr>
<tr>
<td></td>
<td>9709/3 Cutaneous T-cell lymphoma, NOS</td>
</tr>
<tr>
<td></td>
<td>9718/3 Primary cutan. CD30+ T-cell lymphoprolif. Disorder</td>
</tr>
<tr>
<td></td>
<td>9725/3 Hydroa vacciniforme-like lymphoma</td>
</tr>
<tr>
<td></td>
<td>9726/3 Primary Cutaneous gamma-delta T-cell lymphoma</td>
</tr>
<tr>
<td>C809</td>
<td>8152/3 Glucagonoma, malignant</td>
</tr>
</tbody>
</table>